Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Cancer patients taking regular medication for their pain often still have episodes of severe
pain that 'break through' despite their background pain treatment. Fentanyl is a strong,
short-acting painkiller often used to treat this 'breakthrough' pain. Nasalfent contains
fentanyl in a patented drug delivery system called PecSys and is given via a simple nasal
spray. This study will test the efficacy and safety of Nasalfent compared to Immediate
Release Morphine Sulphate in the treatment of breakthrough cancer pain.